Clinical evaluation of penbutolol (Hoe 893d) (beta adrenergic blocker) , alone and in combination with hydrochlorothiazide, in the treatment of arterial hypertension. II. Effect on plasma electrolytes, renal function, plasma renin and aldosterone activity and risk factors, including plasma lipids
Ocón, J.; Piña, C.; Castellet, R.; Vila, R.; del Río, G.; Arnau, C.
Medicina Clinica 85(2): 53-57
1985
ISSN/ISBN: 0025-7753 PMID: 3894828 Document Number: 256392
Risk factors were measured to observe short term changes with penbutolol (P), a new .beta.-blocker (Hoe 893 d). No changes were seen on Ccr and aldosterone followed the expected changes when treated with .beta.-blockers and diuretics. There was no correlation found between control PRA and hypotensive effect when treated with the .beta.-blocker, (r = 0.015), nor with the diuretic (r = 0.17).